APGE — Apogee Therapeutics, Inc. Common Stock

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Apogee Therapeutics, Inc. Common Stock

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clin… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$82.81
Market Cap$6.21B
Float57.8M
Shares Outstanding61.9M
vs. Analyst Target+44.5% to analyst PT
Dividend RateNone
Analyst Target Price$119.69 (9 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2022 N/A -$39.8M N/A -$39.8M
2023 N/A -$84.0M N/A -$75.0M
2024 N/A -$182M -$189,000 -$217M
2025 N/A -$256M -$1.4M -$284M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$66.1M
Sep 2025 N/A -$65.0M
Dec 2025 N/A -$69.4M
Mar 2026 N/A -$74.1M

Ownership & Float

Insider Ownership9.7%
Institutional Ownership131.0%
Short Float16.4%
% of All Funds Holding2.53%
Number of Funds Holding208

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$83.51Near-term / short-term trend
Weekly40-Week SMA$67.40Medium-term trend
Weekly80-Week SMA$53.64Cyclical trend (business cycle)
Weekly200-Week SMA$0.00Secular trend (multi-year)
Monthly10-Month SMA$66.55Near-term monthly trend
Monthly20-Month SMA$53.79Medium-term monthly trend
Monthly40-Month SMA$0.00Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$68.00 support 1.52x 1 months ago
$39.60 support 1.35x 6 months ago

Historical Earnings Reactions (12 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.27% -0.03% 41.67% 3.00% -2.85%
1 Day 2.00% 0.57% 58.33% 12.46% -7.95%
1 Week 4.50% 5.08% 72.73% 28.29% -21.46%
2 Weeks 3.60% 8.10% 60.00% 24.93% -22.06%
1 Month 6.57% 8.95% 60.00% 40.29% -21.98%

Next earnings: July 30, 2026 (63 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.37% 46.3% 136
Tuesday 0.32% 52.3% 149
Wednesday 0.32% 52.1% 146
Thursday 0.23% 51.8% 141
Friday 0.13% 51.0% 145

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 131.0%

Insider Transactions — Smart Summary

Total insider ownership: 9.7%

12-Month Insider Activity Summary

Total Filings33
Net Value-$19.9M
Net Shares Change-1,994,925
% of Float-3.4%
C-Suite Filings32
Clusters Detected7

Key Insiders

NameTitleNet ValueFilingsActivity
Fairmount Funds Management LLC -$134M 1 1 sell
HENDERSON MICHAEL THOMAS Chief Executive Officer -$10.7M 6 N/A
Dambkowski Carl Chief Medical Officer -$2.0M 2 N/A
Henderson Jane Chief Financial Officer -$609,145.6 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-11-07 – 2025-11-14 4 3 -$1.9M 4 C-suite
2025-11-28 – 2025-12-12 5 3 -$5.5M 5 C-suite
2026-01-09 – 2026-01-22 3 3 -$136M 2 C-suite
2026-02-04 – 2026-02-13 3 3 -$1.7M 3 C-suite
2026-03-04 – 2026-03-13 3 3 -$1.9M 3 C-suite
2026-03-27 – 2026-04-10 4 3 -$2.4M 4 C-suite
2026-05-04 – 2026-05-15 3 3 -$2.2M 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-01-22 Fairmount Funds Management LLC -$134M Transaction at $76.30, now +8.5%
2026-01-09 Dambkowski Carl Chief Medical Officer -$1.1M Transaction at $50.35, now +64.5%
2025-12-05 HENDERSON MICHAEL THOMAS Chief Executive Officer -$3.0M Transaction at $75.01, now +10.4%
2026-01-06 Henderson Jane Chief Financial Officer -$609,145.6 Transaction at $76.14, now +8.8%
2025-12-05 Dambkowski Carl Chief Medical Officer -$817,500 Transaction at $75.00, now +10.4%
2026-05-15 HENDERSON MICHAEL THOMAS Chief Executive Officer -$1.6M Transaction at $82.09, now +0.9%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Apogee Therapeutics, Inc. Common Stock (APGE) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for APGE on Trend Edge →